Objective: To investigate the evidence for the use of hyoscine N-butylbromide (HBB) in the treatment of acute renal colic. Methods: A literature search was performed using the keywords ‘hyoscine N-butylbromide', ‘ureteral colic', ‘spasmolytic', ‘anticholinergic' and ‘analgesia'. The articles were given the appropriate level of evidence according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence guidelines. Results: The analgesic effect of HBB as monotherapy is inferior to that of opioids and/or non-steroidal anti-inflammatory drugs (NSAIDs). It does provide an analgesic and antispasmodic effect, but not as long-lasting as NSAIDs. HBB does not serve as an adjunct to opioids. Furthermore, it does not facilitate passage of ureteral stones and has no effect on expulsion rate. Conclusions: HBB is often used where urinary tract smooth muscle spasm is thought to be part of the pathophysiological process. According to the evidence, administration of HBB follows non-peer-reviewed protocols which are based on empiric recommendations. Its role is still unclear, as it appears to have no advantage when used as monotherapy over established forms of analgesia. There appears to be a time-dependent relation to pain reduction following parenteral administration, but this needs to be confirmed by more prospective randomized cohorts.

Keywords:
Hyoscine N-butylbromide, Ureteral colic, Spasmolytic, Anticholinergic, Analgesia
1.
Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007;67:1343-1357.
2.
Oxford Centre for Evidence-Based Medicine - Levels of Evidence (March 2009). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. http://www.cebm.net/index.aspx?o=1025.
3.
Gurbuz MC, Polat H, Canat L, Kilic M, Caskurlu T: Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones. Int Braz J Urol 2011;37:195-200; discussion 201-202.
4.
Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, Becker AJ, Stief CG: In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 2007;35:49-54.
5.
Wanajo I, Tomiyama Y, Tadachi M, Kobayashi M, Yamazaki Y, Kojima M, Shibata N: The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics. Urol Res 2005;33:409-414.
6.
Morita T, Wada I, Saeki H, Tsuchida S, Weiss RM: Ureteral urine transport: changes in bolus volume, peristaltic frequency, intraluminal pressure and volume of flow resulting from autonomic drugs. J Urol 1987;137:132-135.
7.
Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U: The effect of the specific phosphodiesterase-IV-inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo. J Urol 1998;160(3 Pt 1):920-925.
8.
Miyatake R, Tomiyama Y, Murakami M, Park YC, Kurita T: Effects of isoproterenol and butylscopolamine on the friction between an artificial stone and the intraureteral wall in anesthetized rabbits. J Urol 2001;166:1083-1087.
9.
Davenport K, Timoney AG, Keeley FX: Conventional and alternative methods for providing analgesia in renal colic. BJU Int 2005;95:297-300.
10.
Abel G, Erbslöh J, Thoma H: Methods and results of bladder-pressure determination (in German). Z Geburtshilfe Gynakol 1971;175:153-162.
11.
Wolters A, Sökeland J, Weil W, Kopf H: Parasympathicolytic treatment of abnormal neurogenic bladder function: a urodynamic study (author's transl) (in German). Dtsch Med Wochenschr 1980;105:1344-1347.
12.
Habib A, Sharpe P, Anderson S, Francis S, Davidson AC, Smith G: Buscopan for the treatment of pain after laparoscopic sterilisation. Anaesthesia 2001;56:174-176.
13.
Wilson CM, Lillywhite N, Matta B, Mills P, Wiltshire S: Intravenous buscopan for analgesia following laparoscopic sterilisation. Anaesthesia 1999;54:389-392.
14.
Wixforth J, Grond S, Lehmann KA: Ketorolac and butylscopolamine in combination with alfentanil for renal lithotripsy (in German). Schmerz 1998;12:396-399.
15.
Iguchi M, Katoh Y, Koike H, Hayashi T, Nakamura M: Randomized trial of trigger point injection for renal colic. Int J Urol 2002;9:475-479.
16.
Kheirollahi AR, Tehrani M, Bashashati M: A comparison of the effect of intranasal desmopressin and intramuscular hyoscine N-butyl bromide combination with intramuscular hyoscine N-butyl bromide alone in acute renal colic. J Res Med Sci 15:214-218.
17.
Tomiak RH, Barlow RB, Smith PJ: Are there valid reasons for using anti-muscarinic drugs in the management of renal colic? Br J Urol 1985;57:498-499.
18.
Holdgate A, Oh CM: Is there a role for antimuscarinics in renal colic? A randomized controlled trial. J Urol 2005;174:572-575; discussion 575.
19.
Holdgate A, Pollock T: Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2005;2:CD004137.
20.
Yencilek F, Aktas C, Goktas C, Yilmaz C, Yilmaz U, Sarica K: Role of papaverine hydrochloride administration in patients with intractable renal colic: randomized prospective trial. Urology 2008;72:987-990.
21.
Khalifa MS, Sharkawi MA: Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study. J Urol 1986;136:393-395.
22.
al-Waili NS, Saloom KY: Intravenous tenoxicam to treat acute renal colic: comparison with buscopan compositum. J Pak Med Assoc 1998;48:370-372.
23.
Mora Durban MJ, Extramiana Cameno J, Arrizabalaga Moreno M, Paniagua Andrés P, Camp Herrero J, Milla Santos J, del Nogal Saez F, Gimeno Albo F, Moreno Carretero E, Domínguez Granados R: Flurbiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic (in Spanish). Arch Esp Urol 1995;48:867-873.
24.
Lloret J, Vila A, Puig X, Monmany J, Muñoz J, More J: Nifedipine in the treatment of renal colic. Methods Find Exp Clin Pharmacol 1986;8:575-579.
25.
Stankov G, Schmieder G, Zerle G, Schinzel S, Brune K: Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain. World J Urol 1994;12:155-161.
26.
Hofstetter AG, Kriegmair M: Treatment of ureteral colic with glycerol trinitrate (in German). Fortschr Med 1993;111:286-288.
27.
Holmlund D: The pathophysiology of ureteral colic. Scand J Urol Nephrol Suppl 1983;75:25-27.
28.
Ammons WS: Bowditch Lecture. Renal afferent inputs to ascending spinal pathways. Am J Physiol 1992;262(2 Pt 2):R165-R176.
29.
Tytgat GN: Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr Med Res Opin 2008;24:3159-3173.
30.
Schmit A, Björkman S, Åkeson J: Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. Acta Anaesthesiol Scand 2001;45:48-52.
31.
Sostres C, Gargallo CJ, Arroyo MT, Lanas A: Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121-132.
32.
Weiser T, Just S: Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SH-SY5Y cells. Neurosci Lett 2009;450:258-261.
33.
Dellabella M, Milanese G, Muzzonigro G: Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 2003;170(6 Pt 1):2202-2205.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.